$MREO News
Last published 2d ago
- 2d agoMREOMereo BioPharma Group plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoMREOMereo BioPharma Reports Third Quarter 2026 Financial ResultsGlobeNewswireOngoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine
- 2mo agoMREOUltragenyx Corporate Update - MEREO BIOPHARMA GROUP PLCEarnings Call TranscriptsGood afternoon and welcome to the Ultragenyx Pharmaceutical Conference Call to discuss the U.S. Food and Drug Administration approval of GenGlycos, known as DTX401, for the treatment of glycogen storage disease type 1a o
- 3mo agoMREOMereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate HighlightsGlobeNewswireEntered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx
- 3mo agoMREOSentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)PR NewswireSentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory diseaseOn option exercise, Sentynl will have the right to commercialize the product in the
- 3mo agoMREOMereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)GlobeNewswireSentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory diseaseOn option exercise, Sentynl will have the right to commercialize the product in the
- 5mo agoMREOGoldman Sachs 47th Annual Global Healthcare ConferenceMEREO BIOPHARMA GROUP PLCEarnings Call TranscriptsAll right, welcome back everyone. Today we have the pleasure of speaking with Emil Kakas, President and CEO of Ultragenyx. Emil, maybe to start just to level set, you are sitting in front of key phase three Angelman data
- 5mo agoMREOMereo BioPharma Group Plc - Jefferies Global Healthcare Conference in New York - MEREO BIOPHARMA GROUP PLCEarnings Call TranscriptsHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce and welcome Denise Scott-Snight, CEO of Mareo, and John Lewacki, the CSO of Mreo. Thanks so much for joini
- 6mo agoMREONBIX4basebio Announces Appointment of Chief Financial Officer and Board ChangesGlobeNewswireRichard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raised Cambridge, UK, 14 May 2026 –
- 6mo agoMREO2026 GLOBAL HEALTHCARE CONFERENCEMEREO BIOPHARMA GROUP PLCEarnings Call TranscriptsI'm one of the biotech analysts here at B of A. Our next presenting company is Ultragenyx. And here with me are Howard Horn, Chief Financial Officer, and Josh Higa, Head of IR. Thank you for joining us, guys. So I think
- 6mo agoMREOMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireLONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for
- 6mo agoMREOUltragenyx First Quarter 2026 Earnings CallMEREO BIOPHARMA GROUP PLCEarnings Call TranscriptsGood afternoon, and welcome to Ultragenyx's first quarter 2026 Financial Results Conference Call. At this time, all participants are on a listen-only mode. At the end of the prepared remarks, you will have an opportunity
- 8mo agoMREOThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo Lawsuit - MREOPR NewswireThe Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO). Shareholders who purchased shares of MREO ...
- 8mo agoMREOThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo BioPharma Group plc Lawsuit - MREOPR NewswireThe Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO). Shareholders who purchased shares of MREO ...
- 8mo agoMREOMereo BioPharma Group plc Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – MREOGlobeNewswireNEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ:MREO). Shareholders who purchased shares of MREO during the class period
- 9mo agoMREOMereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREOPR NewswireThe Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO). Shareholders who purchased shares of MREO ...
- 9mo agoMREOShareholders of Mereo BioPharma Group plc Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights – MREOGlobeNewswireNEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ:MREO). Shareholders who purchased shares of MREO during the class period
- 10mo agoMREOMereo BioPharma Provides Corporate UpdateGlobeNewswireAdditional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program Cash balance of approximately $41 million as
- 10mo agoMREOMereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis ImperfectaGlobeNewswireNeither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improvements in bone
- 1y agoMREOMereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate HighlightsGlobeNewswireData from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027 LONDON,
- 1y agoMREOāshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2Business Wire- Company's second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - - āshibio has exclusive license to develop and commercialize vantictumab
- 1y agoMREOMereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate HighlightsGlobeNewswireData from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12,
- 1y agoMREOMereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsGlobeNewswireProgress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo
- 1y agoMREOMereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate HighlightsGlobeNewswireOrbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1
- 1y agoMREOMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare ConferenceGlobeNewswireLONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 1y agoMREOMereo BioPharma Provides Update on Lead Clinical ProgramsGlobeNewswireOrbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive
- 1y agoMREOMereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireLONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 1y agoMREOMereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare ConferenceGlobeNewswireLONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 1y agoMREOMereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireSetrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group
- 2y agoMREOMereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare ConferenceGlobeNewswireLONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 2y agoMREOMereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates
- 2y agoMREOMereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-MarketGlobeNewswireLONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an
- 2y agoMREORAREUltragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)GlobeNewswire14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment resulted in continued,
- 2y agoMREOMereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare ConferenceGlobeNewswireLONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 2y agoMREOMereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireLONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results
- 2y agoMREOMereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswireLONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 2y agoMREOMereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePhase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions
- 2y agoMREOMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma ConferenceGlobeNewswireLONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 2y agoMREORAREMereo BioPharma Provides Update on Pipeline Progress and Corporate DevelopmentsGlobeNewswirePhase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024,
- 3y agoMREORAREMereo BioPharma Reports on Recent Program Developments and Provides Financial UpdateGlobeNewswireLONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent
- 3y agoMREORAREUltragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)GlobeNewswirePhase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx
- 3y agoMREORAREUltragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)GlobeNewswireNOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI)
- 3y agoMREOMereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare ConferenceGlobeNewswireLONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 3y agoMREOMereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate UpdateGlobeNewswireLONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim
- 3y agoMREORAREUltragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)GlobeNewswirePivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif.,
- 3y agoMREORAREUltragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)GlobeNewswirePediatric data show substantial induction of bone production in 1 week and a large increase in bone formation within 3 months of initiating monthly setrusumab treatment Phase 3 sites beginning to screen patients
- 3y agoMREOMereo BioPharma to Present at the Jefferies Healthcare ConferenceGlobeNewswireLONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise
- 3y agoMREOPhase 2 Data from "ASTRAEUS" Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International ConferenceGlobeNewswireLONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), ("Mereo" or "the Company"), a clinical-stage biopharmaceutical company focused on rare diseases today announced that data from the Phase
- 3y agoMREOMereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireLONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it received written
- 3y agoMREOMereo BioPharma Announces Listing Transfer to Nasdaq Capital MarketGlobeNewswireLONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received